Heparins and heparinoids: Occurrence, structure and mechanism of antithrombotic and hemorrhagic activities
No Thumbnail Available
Date
2004-01-01
Authors
Nader, Helena Bonciani [UNIFESP]
Lopes, Carla Cristina [UNIFESP]
Rocha, Hugo Alexandre de Oliveira [UNIFESP]
Santos, Elizeu Antunes dos [UNIFESP]
Dietrich, Carl Peter [UNIFESP]
relationships.isAdvisorOf
item.page.type-of
Resenha
Journal Title
Journal ISSN
Volume Title
Abstract
The correlation between structure, anticloting, antithrombotic and hemorrhagic activities of heparin, heparan sulfate, low molecular weight heparins and heparin-like compounds from various sources that are in used in clinical practice or under development is briefly reviewed. Heparin-like molecules composed exclusively of iduronic acid 2-O-sulfate residues have weak anticloting activities, whereas molecules that contain both iduronic acid 2-O sulfate, iduronic acid and small amounts or glucuronic acid, such as heparin, or mixed amounts of glucuronic and iduronic acids (mollusk heparins) possess high anticloting and anti-Xa activities. These results also suggest that a proper combination of these elements might produce a strong antithrombotic agent. Heparin isolated from shrimp mimics the pharmacological activities of low molecular weight heparins. A heparan sulfate derived from bovine pancreas and a sulfated fucan from brown algae have a potent antithrombotic activity in arterial and venous thrombosis model in vivo with a negligible activity upon the serine-proteases of the coagulation cascade in vitro. These and other results led to the hypothesis that antithrombotic activity of heparin and other antithrombotic agents is due at least in part by their action on endothelial cells stimulating the synthesis of an antithrombotic heparan sulfate. All the antithrombotic agents derived from heparin and other heparinoids have hemorrhagic activity. Exceptions to this are a heparan sulfate from bovine pancreas and a sulfated fucan derived from brown algae, which have no hemorrhagic activity but have high antithrombotic activities in vivo. Once the structure of these compounds are totally defined it will be possible to design an ideal antithrombotic.
Description
Citation
Current Pharmaceutical Design. Hilversum: Bentham Science Publ Ltd, v. 10, n. 9, p. 951-966, 2004.